Navigation Links
Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
Date:7/28/2014

SUNNYVALE, Calif., July 28, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will hold a conference call and audio webcast to discuss financial results for the second quarter of 2014 after the NASDAQ Market closes on Thursday, July 31, 2014 at 4:30 p.m. ET.

Conference call and webcast details:

Date: July 31, 2014
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877) 303-7908
International: (678) 373-0875

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics

Pharmacyclics® is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify and control promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Pharmacyclics markets IMBRUVICA and has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

Pharmacyclics is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances s
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
2. WuXi PharmaTech to Partner with Pharmacyclics
3. Pharmacyclics Reports Third Quarter 2013 Results
4. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
5. Pharmacyclics Reports Second Quarter 2013 Results
6. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
7. Pharmacyclics Reports First Quarter 2013 Results
8. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
9. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
10. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
11. Pharmacyclics, Inc. Prices Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... MOUNTAIN VIEW, Calif. , Oct. 22, ... 11:00 a.m. EDTLOCATION: Online, complimentary registration available ... Group Team Leader Archana Vidyasekar and Visionary ... VargheseBrain-controlled computers, WiFi-like wireless electricity, self-assembling materials, ... top ten technologies which will transform our ...
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... Mitsubishi Chemical Medience Corporation announced today that the ... 510(k) premarketing notification clearance to the PATHFAST® cTnI-II ... for its sale in the United States. The ... PATHFAST analysis system, a unique, self-contained, bench-top chemi-luminescence ...
... Reportlinker.com announces that a new market research ... Distributor Analysis of the Pharmaceutical ... http://www.reportlinker.com/p0552921/Distributor-Analysis-of-the-Pharmaceutical-Industry-in-Key-SADC-Countries.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu ... to present an overview of the pharmaceutical ...
Cached Medicine Technology:Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S. 2Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S. 3Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3
(Date:10/22/2014)... 22, 2014 During the Western United ... supply runs dangerously low, Southern Oregon’s water is proving ... despite the lowest mountain snow pack on record in ... and early autumn.* That was the observation of journalist-hikers ... book “Hiking Southern Oregon,” during an interview with water ...
(Date:10/22/2014)... Texas (PRWEB) October 22, 2014 ... of completing their continuing education at home or ... have access to 20 brand new, premium Seminar-on-Demand ... robust catalog of over 2,000 hours ... fully customize their educational experience. With such a ...
(Date:10/22/2014)... 2014 Although there are only 24 hours in ... people who have trouble finding time within their busy schedules for ... long periods of time to get in shape. Here are five ... the go. , Change Up Your Commute , Consider riding ... add some exercise into your daily routine. If you must use ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... and length may be showing a genetic propensity for obesity ... genes have been linked to increased body fat, but the ... lean muscle, the researchers said. At 1 year, kids ... 2 and 3, however, these genes were linked to excessive ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... Boston (Jan. 26, 2012) Research to Prevent Blindness ... specialist James Chodosh, M.D., M.P.H., a $150,000 Senior Scientific ... recognized scientists conducting eye research at medical institutions in ... respected for his work on viral infections of the ...
... of advanced head and neck cancer patients treated with ... positive outcomes than patients treated with radiation therapy alone ... according to a study presented at the Multidisciplinary Head ... and SNM., Researchers analyzed two subgroups totaling 410 patients ...
... to the anti-cancer drug erlotinib when it is administered before ... smoke, according to a study presented at the Multidisciplinary Head ... SNM., Erlotinib is an oral anti-cancer drug that can slow ... on the surface of the cancer cells. Early detection of ...
... Esposito HealthDay Reporter , WEDNESDAY, Jan. 25 (HealthDay ... known as mild cognitive impairment -- often precede Alzheimer,s disease, ... risk for these troubles than women. Lead researcher ... Olmsted County, Minn., who were between 70 and 89 years ...
... , WEDNESDAY, Jan. 25 (HealthDay News) -- U.S. ... depression and suicide, three new studies indicate. In ... war zone deployment in Iraq or Afghanistan, and found ... problems and alcohol and drug abuse. Nearly 14 ...
... fat and cholesterol before pregnancy were at higher risk for ... fat and cholesterol, according to researchers at the National Institutes ... a form of diabetes seen during pregnancy. Gestational diabetes ... in the newborn. Women whose diets were high in ...
Cached Medicine News:Health News:Erlotinib dose-adjusted for smoking status effective as first treatment for head and neck cancer 2Health News:Men at Higher Risk for Mental Decline That Precedes Alzheimer's 2Health News:Men at Higher Risk for Mental Decline That Precedes Alzheimer's 3Health News:U.S. Soldiers Face Host of Mental Health Issues 2Health News:U.S. Soldiers Face Host of Mental Health Issues 3Health News:High animal fat diet increases gestational diabetes risk 2
... OptiMumm™ smoke evacuator is ... complete smoke evacuation system ... AccuVac™ smoke evacuation attachment, ... and either the Force ...
Turnstile casting stand for easy and safe casting. The compact system sets up quickly and stores conveniently, and the non-stick coating prevents fiberglass or plaster from adhering to surface....
Bone cement with Gentamicin 2.5%....
... Techno-Aide provides the highest level ... highest quality lead protective eyewear. ... + tolerance allowed. Mfg supervised by ... All lens meet or exceed standards ...
Medicine Products: